Unit dose prazosin 5 mg cartons recalled over nitrosamine impurity
Amerisource Health Services is recalling 3,410 unit dose cartons of Prazosin Hydrochloride Capsules 5 mg over N-nitroso Prazosin impurity C above the acceptable intake limit.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Scored 3 under the risk-of-harm criterion: a named nitrosamine impurity above its acceptable intake limit is a defined safety threshold breach, with no injuries reported.
Plain-English summary
Prazosin Hydrochloride Capsules, USP, 5 mg, in 20-capsule (5x4) unit dose cartons distributed by American Health Packaging of Columbus, Ohio, are being recalled for failed impurities and degradation specifications.
The recall follows the presence of N-nitroso Prazosin impurity C above the acceptable intake limit set by the Carcinogenic Potency Categorization Approach.
The recall covers 3,410 cartons from lots 1016996, 1018336 and 1021220 (which expired 30 November 2025) and 1022421 and 1025017 (expiring 31 August 2026), carrying carton NDC 60687-572-32 and unit dose NDC 60687-572-33. The product was distributed nationwide in the United States. The FDA has classified the recall as Class II.
This is a unit dose presentation used in institutional settings. Facilities and pharmacies holding an affected lot should quarantine it and follow the firm's instructions; patients should speak to their pharmacy or prescriber rather than stopping treatment on their own.
The recalled product
- Product
- PRAZOSIN HYDROCHLORIDE (PRAZOSIN HYDROCHLORIDE)
- Brand
- PRAZOSIN HYDROCHLORIDE
- Manufacturer
- Amerisource Health Services LLC
- Category
- Drug — Antihypertensive
- Affected units
- 3,410
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #: 1016996
- 1018336
- 1021220
- Exp. Date 11/30/2025
- 1022421
- 1025017
- Exp. Date 08/31/2026.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Amerisource Health Services LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · PRAZOSIN HYDROCHLORIDE
- HighPrazosin hydrochloride further lots recalled over nitrosamine impurity levels
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride tablets recalled over nitrosamine impurity above limits
FDA (Drugs) · 2026-04-08
- HighPrazosin capsules recalled over nitrosamine impurity above the acceptable intake limit
FDA (Drugs) · 2025-11-05
- HighUnit dose prazosin 1 mg cartons recalled over nitrosamine impurity
FDA (Drugs) · 2025-11-05
Same manufacturer · Amerisource Health Services LLC
See all →- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighOxycodone blister cards recalled over seals that let tablets fall out
FDA (Drugs) · 2026-02-18
- HighUnit dose prazosin 2 mg cartons recalled over nitrosamine impurity
FDA (Drugs) · 2025-11-05
Same hazard · nitrosamine
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over a nitrosamine impurity
FDA (Drugs) · 2026-02-11
- HighClomipramine 25 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12